HSGX Histogenics Corporation

0.18
0  -1%
Previous Close 0.18
Open 0.17
Price To Book -2.93
Market Cap 16649530
Shares 94,599,601
Volume 2,376,116
Short Ratio
Av. Daily Volume 11,016,193

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be suspended - noted December 21, 2018.
NeoCart
Cartilage defects in the knee

Latest News

  1. How Will Histogenics Shareholders Fare in the Merger with Ocugen
  2. Histogenics News: Why Did HSGX Stock Soar Today?
  3. Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger
  4. Histogenics to serve as shell for Pennsylvania biotech in reverse-merger
  5. Malvern gene therapy developer to acquire publicly traded Boston company
  6. Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
  7. Edited Transcript of HSGX earnings conference call or presentation 9-Nov-17 1:30pm GMT
  8. Biotech Bounce Just Getting Started
  9. Jonathan Lieber Joins Danforth Advisors as Managing Director
  10. Biotech Stocks on the Rise
  11. Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?
  12. Best Ways to Play Biotech Rally
  13. The Next Big Biotech Breakout
  14. 4 Healthcare Stocks To Watch On Friday (1/4/19)
  15. Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway
  16. Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway
  17. New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018
  18. Cell therapy biotech Vericel eyes $2B knee repair market
  19. Histogenics: 3Q Earnings Snapshot
  20. Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results